lorazepam 2.5 mg tablets
morningside healthcare (malta) limited - lorazepam - tablet - 2.5 milligram(s) - benzodiazepine derivatives; lorazepam
oxazepam 10mg tablets
tillomed laboratories ltd - oxazepam - oral tablet - 10mg
oxazepam 15mg tablets
tillomed laboratories ltd - oxazepam - oral tablet - 15mg
clobazam essential pharmaceuticals 1 mg/ml oral suspension
essential pharmaceuticals limited - clobazam - oral suspension - 1 milligram(s)/millilitre - clobazam
lexotan 1.5 milligram tablets
roche products limited - bromazepam - tablets - 1.5 milligram - benzodiazepine derivatives
lexotan 3 milligram tablets
roche products limited - bromazepam - tablets - 3 milligram - benzodiazepine derivatives
librium 10 milligram capsule
meda health sales ireland limited - chlordiazepoxide hydrochloride - capsule - 10 milligram - benzodiazepine derivatives
librium 5 milligram capsule
meda health sales ireland limited - chlordiazepoxide hydrochloride - capsule - 5 milligram - benzodiazepine derivatives
perizam 1mg/ml oral suspension
rosemont pharmaceuticals ltd - clobazam - oral suspension - 1 mg/ml - anxiolytics - it indicated in adults for the short-term symptomatic treatment (2-4 weeks) only of anxiety that is severe, disabling or subjecting the individual to unacceptable distress. in treatment of anxiety states associated with affected disorders, must only be used in conjunction with adequate treatments for the underlying disorder. in patients with schizophrenic or other psychotic illnesses, use of benzodiazepines is recommended only for short term symptomatic management of hyperarousal and agitation. benzodiazepines do not possess antipsychotic properties. it may be used as adjunctive therapy in epilepsy in adults or children over 6, if standard treatment with one or more anticonvulsants has failed.
perizam 2mg/ml oral suspension
rosemont pharmaceuticals ltd - clobazam - oral suspension - 2mg/ml - anxiolytics - it indicated in adults for the short-term symptomatic treatment (2-4 weeks) only of anxiety that is severe, disabling or subjecting the individual to unacceptable distress. in treatment of anxiety states associated with affected disorders, must only be used in conjunction with adequate treatments for the underlying disorder. in patients with schizophrenic or other psychotic illnesses, use of benzodiazepines is recommended only for short term symptomatic management of hyperarousal and agitation. benzodiazepines do not possess antipsychotic properties. it may be used as adjunctive therapy in epilepsy in adults or children over 6, if standard treatment with one or more anticonvulsants has failed.